Teva hire, structure change may point to eventual separation, says BMO Capital

BMO Capital views Teva's (TEVA) hiring of former Actavis (ACT) executive Sigurdur Olafsson as "tremendously" good news. The firm believes the hiring and the company's new structure could point to the potential for an eventual separation of the Teva's generic and branded units, though BMO thinks that is very unlikely in the near term. The firm maintains its Outperform rating on Teva.

Advertisement